Cognizant announces a strategic collaboration with NVIDIA to leverage generative AI (gen AI) technology through the NVIDIA BioNeMo platform. This partnership aims to revolutionize drug discovery processes within the life sciences industry, offering solutions to complex challenges and accelerating the development of life-saving treatments.
Addressing Challenges in Drug Discovery:
Traditional drug discovery methodologies are known for their complexity and resource-intensive nature. Cognizant aims to tackle these challenges by harnessing the power of generative AI, which enables researchers to sift through extensive datasets more rapidly and accurately predict interactions between drug compounds.
Quote from Anna Elango, EVP of Cognizant’s Core Technologies & Insights:
“More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all.”
Benefits of Collaboration:
By combining Cognizant’s deep expertise in life sciences and AI with NVIDIA’s pretrained, industry-specific generative AI models provided by BioNeMo, clients will have access to a suite of model-making services. These offerings include pretrained models, cutting-edge frameworks, and APIs, enabling quicker customization of enterprise models using proprietary data with reduced manual intervention.
Quote from Alvin DaCosta, VP of Global Consulting Partner Organization at NVIDIA:
“Generative AI will drive the next wave of enterprise productivity gains across industries, enabled by the NVIDIA AI Enterprise software platform. Using NVIDIA BioNeMo, Cognizant will help provide its life sciences clients with advanced, secure and reliable AI services to drive improved outcomes with custom drug discovery applications.”
Cognizant’s Commitment to Innovation:
Cognizant has a track record of collaborating with leading global firms in pharmaceuticals, biotech, and medical devices. This partnership underscores Cognizant’s commitment to enhancing science, improving patient outcomes, and increasing business value across the life sciences value chain.
Future Endeavors and NVIDIA AI Center of Excellence:
Cognizant plans to explore additional applications in collaboration with NVIDIA, extending the benefits of generative AI to industries such as manufacturing and automotive engineering. To further drive innovation, Cognizant intends to establish an NVIDIA AI Center of Excellence this year, leveraging NVIDIA technologies for the benefit of clients worldwide.
Conclusion:
The partnership between Cognizant and NVIDIA signifies a significant step forward in applying generative AI to enhance drug discovery processes. By leveraging cutting-edge technologies, both companies aim to empower life sciences clients with advanced solutions, ultimately contributing to improved patient outcomes and driving innovation across industries.
About Cognizant:
Cognizant (Nasdaq: CTSH) engineers modern businesses, helping clients modernize technology, reimagine processes, and transform experiences to stay ahead in our fast-changing world.
